Anti-TIGIT immunotherapy drugs behave differently in macaques and humans. The findings may explain why immunotherapy anti-TIGIT antibodies have failed in Phase III trials.
UC Davis Health cardiologists became the first in the world to treat patients with mitral and tricuspid regurgitation using a novel valve repair system.